Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients

被引：0
|
作者：
Gorumlu, Gurbuz [1 ]
Kucukzeybek, Yuksel [1 ]
Karabulut, Bulent [1 ]
Terek, Mustafa C. [1 ]
Uslu, Ruchan [1 ]
Sanli, Ulus A. [1 ]
Akman, Levent [1 ]
Ozsaran, Aydin [1 ]
Dikmen, Yilmaz [1 ]
Goker, Erdem [1 ]
机构：
[1] Ege Univ, Izmir, Turkey
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [11] Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations
    Safra, T.
    Borgato, L.
    Nicoletto, M.
    Rolnitzky, L.
    Curtin, J.
    Geva, R.
    Peles, S.
    Grenader, T.
    Gabizon, A.
    Muggia, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [12] Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Casarin, Alessandra
    Randon, Giovanni
    Nardin, Margherita
    Baretta, Zora
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Rigamonti, Claudia
    Conte, Pier Franco
    TUMORI, 2015, 101 (05) : 506 - 510
  • [13] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [14] Biweekly pegylated liposomal doxorubicin (Caelyx/Doxil) in heavily pretreated patients with metastatic breast cancer.
    Schmid, P
    Schulz, CO
    Dieing, A
    Lehenbauer-Dehm, S
    Flath, RA
    Sezer, O
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S204 - S204
  • [15] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [16] The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients
    Hensley, ML
    Hoppe, B
    Leon, L
    Sabbatini, P
    Aghajanian, C
    Chi, D
    Spriggs, DR
    GYNECOLOGIC ONCOLOGY, 2001, 82 (03) : 464 - 469
  • [17] Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients
    Bourgeois, Hugues
    Joly, Florence
    Pujade-Lauraine, Eric
    Cure, Herve
    Guastalla, Jean Paul
    Ferru, Aurelie
    Chabrun, Virginie
    Chieze, Stephanie
    Tourani, Jean-Marc
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 399 - 404
  • [18] Pegylated liposomal doxorubicin in ovarian cancer
    Green, Andrew E.
    Rose, Peter G.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2006, 1 (03): : 229 - 239
  • [19] Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer [REOC).
    Grenier, N
    Lebel, V
    Gill, M
    Mitchinson, K
    Foster, M
    Lewis, S
    Sebborn, K
    Rodgers, A
    Pouliot, JF
    Mullen, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 778S - 778S
  • [20] Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
    Monk, Bradley J.
    Herzog, Thomas J.
    Kaye, Stanley B.
    Krasner, Carolyn N.
    Vermorken, Jan B.
    Muggia, Franco M.
    Pujade-Lauraine, Eric
    Park, Youn C.
    Parekh, Trilok V.
    Poveda, Andres M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) : 2361 - 2368
12345